BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iida H, Osaki R, Fujimoto T, Maehira H, Mori H, Kitamura N, Andoh A, Tani M. Interval between hepatocellular carcinoma treatment and interferon-free direct-acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence. Mol Clin Oncol 2019;11:99-105. [PMID: 31289685 DOI: 10.3892/mco.2019.1847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Kamal A, Elmoety AAA, Rostom YA, Shater MS, Lashen SA. Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study. Clin Exp Hepatol 2021;7:66-73. [PMID: 34027117 DOI: 10.5114/ceh.2021.104397] [Reference Citation Analysis]
2 Kamal A, Elsheaita A, Abdelnabi M. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate. World J Clin Cases 2022; 10(6): 1764-1774 [DOI: 10.12998/wjcc.v10.i6.1764] [Reference Citation Analysis]